Flotillin-1 (Flot-1) has been shown to regulate cancer progression, but the regulatory role of post-translational modifications of Flot-1 on cancers remains elusive. Herein, we show that up-regulated E2 conjugating enzyme UBC9 sumoylates Flot-1 at Lys-51 and Lys-195 with small ubiquitin-like modifier (SUMO)-2/3 modification in metastatic prostate cancer. Mitogen induced the sumoylation and nuclear translocation of Flot-1. The nuclear-targeted Flot-1 physically interacted with Snail, and inhibited Snail degradation through the proteasome in a sumoylation-dependent manner, thereby promoting epithelial-to-mesenchymal transition (EMT). Sumoylation of Flot-1 by up-regulated UBC9 in human metastatic prostate cancer tissues and prostate cancer cells with high metastatic potential positively correlated with the stabilization of Snail and the induction of Snail-mediated EMT genes in the metastatic prostate cancer. Our study reveals a new mechanism of sumoylated Flot-1-mediating Snail stabilization, and identifies a novel sumoylated Flot-1-Snail signaling axis in EMT of metastatic prostate cancer.
Here, we explored flotillin-1-mediated regulation of insulin-like growth factor-1 (IGF-1) signaling. Flotillin-1-deficient cells exhibited a reduction in the activation of IGF-1 receptor (IGF-1R), ERK1/2 and Akt pathways, and the transcriptional activation of Elk-1 and the proliferation in response to IGF-1 were reduced in these cells. We found that IGF-1-independent flotillin-1 palmitoylation at Cys34 in the endoplasmic reticulum (ER) was required for the ER exit and the plasma membrane localization of flotillin-1 and IGF-1R. IGF-1-dependent depalmitoylation and repalmitoylation of flotillin-1 sustained tyrosine kinase activation of the plasma-membrane-targeted IGF-1R. Dysfunction and blocking the turnover of flotillin-1 palmitoylation abrogated cancer cell proliferation after IGF-1R signaling activation. Our data show that flotillin-1 palmitoylation is a new mechanism by which the intracellular localization and activation of IGF-1R are controlled.
Here, we have identified a retrograde transport pathway of caveolin‐2 (cav‐2) for its regulatory function in the nucleus. Confocal microscopy analysis, photoactivation experiments and subcellular fractionation revealed that cav‐2 localized in the Golgi was transported to the inner nuclear membrane (INM) in response to insulin. Exogenous caveolin‐1 (cav‐1) and P132L‐cav‐1 expression did not affect the Golgi localization and insulin‐induced INM targeting of cav‐2. Cav‐2DKV mutant in the endoplasmic reticulum (ER) was unable to translocate to the INM in response to insulin. The GTP‐bound form of Rab6 promoted, but Rab6 siRNA and the GDP‐bound form of Rab6 abrogated, retrograde trafficking of cav‐2 from the Golgi to ER. Colchicine or nocodazole treatment abolished insulin‐induced INM targeting of cav‐2. Knock down of gp210 inhibited insulin‐induced import of cav‐2 from ER/outer nuclear membrane (ONM) to the INM. The INM‐targeted cav‐2 prevented heterochromatinization and promoted transcriptional activation of Elk‐1 and signal transducer and activator of transcription 3 (STAT3). The results provide molecular mechanisms for insulin‐induced INM translocation of cav‐2 initiated (i) by Golgi‐to‐ER retrograde trafficking of cav‐2 via microtubule‐based Rab6‐GTP‐dependent transport and subsequently processed (ii) by gp210‐mediated import of cav‐2 from ER/ONM to INM.